A Phase 4 interventional study of Sham Injection and Recombinant human hyaluronidase PH20 in Type 1 Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Halozyme Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 786th largest by enrollment of the 1,242 interventional ones that give a count, is one of 47 that started in 2011, is one of 74 in phase 4, and was the 420th registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 47 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate consistency of accelerated insulin absorption and onset-of-action and shortened duration of action for bolus insulin infusions after pretreatment with 150 units (U) of Hylenex® (recombinant human hyaluronidase PH20 [rHuPH20]) injection at the time of infusion set insertion compared to sham injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16. Each Phase was separated by a washout period of 5 to 21 days.
Drug: Sham Injection · Drug: Insulin aspart · Drug: Insulin lispro
In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20). Each Phase was separated by a washout period of 5 to 21 days.
Drug: Recombinant human hyaluronidase PH20 · Drug: Insulin aspart · Drug: Insulin lispro
Also known as: rHuPH20, PH20, Hylenex
Also known as: Novolog, Aspart
Also known as: Humalog, Lispro
Early Insulin Exposure (%AUC[0-60])
Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0 360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, and 60 minutes postdose during a euglycemic clamp.
Time frame: 10 minutes predose; 0, 5, 10, 15, 20, 30, 45, and 60 minutes postdose on Days 1 and 4
Maximum Glucose Infusion Rate (GIRmax)
Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose on Days 1 and 4
Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax)
Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose on Days 1 and 4
Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max)
Early and late tGIR50%max are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose on Days 1 and 4
Time to 50% Total Glucose Infused (50%Gtot)
Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose on Days 1 and 4
Area Under the Glucose Concentration Curve (AUC[0-360])
Area under the glucose concentration curve from 0 to 360 minutes (AUC\[0-360\]) is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 30 minutes and 10 minutes predose; 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose on Days 1 and 4
Duration of Insulin Action (AUMC[0-360]/AUC[0-360])
Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]). AUCM is the total area under the first moment curve. First moment curve is obtained by plotting concentration-time versus time. It can be used to measure how long a drug stays in the body. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 10 minutes predose; 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose on Days 1 and 4
| Milestone | Insulin-rHuPH20, Then Insulin-sham | Insulin-sham, Then Insulin-rHuPH20 |
|---|---|---|
| Started | 12 | 13 |
| Received at least 1 dose of study drug | 12 | 13 |
| Completed | 10 | 12 |
| Not completed | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Insulin-rHuPH20, Then Insulin-sham | Insulin-sham, Then Insulin-rHuPH20 |
|---|---|---|
| Started | 10 | 12 |
| Completed | 10 | 12 |
| Not completed | 0 | 0 |
| Milestone | Insulin-rHuPH20, Then Insulin-sham | Insulin-sham, Then Insulin-rHuPH20 |
|---|---|---|
| Started | 10 | 12 |
| Completed | 10 | 12 |
| Not completed | 0 | 0 |
Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0 360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, and 60 minutes postdose during a euglycemic clamp.
| percentage of AUC(0-60) | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Day 1 | 33.53 ± 11.81 | 17.85 ± 8.24 |
| Day 4 | 39.45 ± 9.72 | 33.52 ± 10.78 |
Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| milligrams/kilogram/minute | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Day 1 | 13.47 ± 5.46 | 11.14 ± 4.21 |
| Day 4 | 10.75 ± 3.73 | 11.83 ± 3.26 |
Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| minutes | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Day 1 | 78.95 ± 37.16 | 132.62 ± 55.07 |
| Day 4 | 81.86 ± 45.99 | 97.38 ± 47.31 |
Early and late tGIR50%max are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| minutes | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Early tGIR50%, Day 1 | 40.33 ± 20.13 | 54.67 ± 33.97 |
| Late tGIR50%, Day 1 | 114.52 ± 54.33 | 152.14 ± 61.00 |
| Early tGIR50%, Day 4 | 32.57 ± 14.50 | 39.67 ± 15.51 |
| Late tGIR50%, Day 4 | 113.24 ± 48.72 | 126.71 ± 50.37 |
Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| minutes | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Day 1 | 40.33 ± 20.13 | 32.57 ± 14.50 |
| Day 4 | 54.67 ± 54.67 | 39.67 ± 15.51 |
Area under the glucose concentration curve from 0 to 360 minutes (AUC\[0-360\]) is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| picomoles*minutes/liter | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Day 1 | 1312.41 ± 627.33 | 1199.54 ± 535.80 |
| Day 4 | 1063.77 ± 500.06 | 1139.65 ± 414.94 |
Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]). AUCM is the total area under the first moment curve. First moment curve is obtained by plotting concentration-time versus time. It can be used to measure how long a drug stays in the body. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| ratio | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| Day 1 | 119.02 ± 21.18 | 154.03 ± 27.58 |
| Day 4 | 111.25 ± 20.59 | 120.57 ± 20.85 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin (Aspart or Lispro)-rHuPH20 | — | 0/24 (0%) | 13/24 (54.2%) |
| Insulin (Aspart or Lispro)-Sham | — | 0/23 (0%) | 9/23 (39.1%) |
| Event | Insulin (Aspart or Lispro)-rHuPH20 | Insulin (Aspart or Lispro)-Sham |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/24 | 4/23 |
| HeadacheNervous system disorders | 2/24 | 3/23 |
| Injection site painGeneral disorders | 3/24 | 1/23 |
| Injection site pruritusGeneral disorders | 1/24 | 2/23 |
| NauseaGastrointestinal disorders | 2/24 | 1/23 |
| VomitingGastrointestinal disorders | 2/24 | 0/23 |
| Injection site inflammationGeneral disorders | 0/24 | 1/23 |
| TendernessGeneral disorders | 0/24 | 1/23 |
| Upper respiratory tract infectionInfections and infestations | 1/24 | 1/23 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/24 | 1/23 |
All enrolled participants.
| Age, Continuous(years) | All Enrolled Participants |
|---|---|
| Mean | 31.6 ± 9.13 |
| Sex: Female, Male(Participants) | All Enrolled Participants |
|---|---|
| Female | 14 |
| Male | 11 |
| Race (NIH/OMB)(Participants) | All Enrolled Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 0 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | All Enrolled Participants |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Enrolled Participants |
|---|---|
| United States | 25 |
The record gives a start of Dec 2011, a primary completion of Aug 2012 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)